Surrozen, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| SRZN | KOD | FDMT | IRD | YDES | NBP | |
|---|---|---|---|---|---|---|
| Market cap | 553.72M | 6.19B | 678.40M | 355.25M | 492.28M | 117.16M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -7.6 | -28.7 | -3.0 | -6.0 | — | -0.8 |
| Price/book | -1.7 | 101.1 | 1.7 | -27.2 | 110.3 | 0.6 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +153.20% | +482.90% | +12.45% | +110.34% | −26.14% | −75.89% |
| Today | +5.08% | −0.38% | +2.76% | +8.65% | +7.84% | 0.00% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All SRZN news ›Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema
First patient expected to be dosed in the DUET study in the fourth quarter of 2026 Milestone triggers second closing of March 2025 private placement expected to provide approximately $95.1M in gross proceeds The Company expects to dose the…
Cantor Fitzgerald Sticks to Their Buy Rating for Surrozen (SRZN)
In a report released yesterday, Steven Seedhouse from Cantor Fitzgerald maintained a Buy rating on Surrozen, with a price target of $40.00. According to TipRanks, Seedhouse is a 4-star analyst with an average return of 9.8% and a 41.88%…
Surrozen price target raised to $54 from $44 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Surrozen (SRZN) to $54 from $44 and keeps a Buy rating on the shares. The firm believes Merck’... Surrozen price target raised to $54 from $44 at H.C. Wainwright H.C. Wainwright raised the…
FDA clears Surrozen's IND for DME therapy
Surrozen, Inc. has received FDA clearance for its investigational new drug (IND) application for SZN-8141 for the treatment of diabetic macular edema (DME). The update follows less than 1 month after the biotech company announced its…
What Hit Syndax (NASDAQ:SNDX), Summit (NASDAQ:SMMT), Scribe (NASDAQ:SCTX) and Surrozen (NASDAQ:SRZN) on October 13?
Explore 3 Stock Ideas & Industry Insights Download Free Report Syndax Pharmaceuticals (NASDAQ:SNDX): Down 17.85% on a Gap Summit Therapeutics (NASDAQ:SMMT): Down 7.27% on a News Tag Scribe Therapeutics (NASDAQ:SCTX): Down 7.01% on Light…
Surrozen Sees Unusually Large Options Volume (NASDAQ:SRZN)
Posted by Danessa Lincoln on Oct 12th, 2026 Surrozen, Inc. (NASDAQ:SRZN – Get Free Report) saw some unusual options trading on Monday. Traders acquired 4,277 call options on the stock. This is an increase of 233% compared to the typical…
Surrozen (NASDAQ:SRZN) and AbCellera Biologics (NASDAQ:ABCL) Head-To-Head Contrast
Posted by Sarita Garza on Oct 7th, 2026 Surrozen (NASDAQ:SRZN – Get Free Report) and AbCellera Biologics (NASDAQ:ABCL – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses…
Surrozen secures FDA clearance for SZN-8141 clinical trial
Surrozen intends to dose the first patient in its DUET clinical trial during the fourth quarter of 2026. The US Food and Drug Administration (FDA) has cleared Surrozen’s investigational new drug (IND) application for SZN-8141 to begin…
Surrozen Announces Closing of Second Tranche of March 2025 Private Placement for $95.1 Million
markets.businessinsider.com Surrozen Announces Closing of Second Tranche of March 2025 Private Placement for $95.1 Million SOUTH SAN FRANCISCO, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Su
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- markets.businessinsider.com5
- themarketsdaily.com2
- clinicaltrialsarena.com1
- globenewswire.com1
- kalkine.ca1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 12 articles, not a forecast.